维普期刊资源整合服务平台（V6.5）

22篇 您的检索式：作者名="Herrlinger KR"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Mechanisms of disease:defensins in gastrointestinal disease显示文摘	WEHKAMP J FELLERMANN K HERRLINGER KR	2005	Nat Clin Pract Gastroenterol Hepatol2005，2，：	1
2	Mechanisms of disease: defensins in gastrointestinal diseases 显示文摘	Wehkamp J Fellermann K Herrlinger KR	2005	Nat Clin Pract Gastroenterol Hepatol2005，2，9：	1
3	Mechanisms of disease:defensins in gastrointestinal diseases 显示文摘	Wehkamp J Fellermann K Herrlinger KR	2005	Nat Clin Pract Gastroenterol Hepatol2005，2，9：	1
4	Crohn's disease:a defensin deficiency syndrome显示文摘	Fellermann K Wehkamp J Herrlinger KR		0，，06：	1
5	Response of refractory colitis to intravenous or oral tacrilimus (FK506)显示文摘	Fellermann K Tanko Z Herrlinger KR	2002	Imflamm Bowel Dis2002，8，5：	1
6	Innate immuni- ty and colonic inflammation : enhanced expression of epithe- lial alpha-de-fensins显示文摘	Wehkamp J Schwind B Herrlinger KR	2002	Dig Dis Sci2002，47，6：	1
7	ABCB1 single-nucleotide polymorphisms determine tacroli- mus response in patients with ulcerative colitis显示文摘	Herrlinger KR Koc H Winter S	2011	Clin Pharmacol Ther2011，89，3：	1
8	Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing 显示文摘	Teml A Schaeffeler E Herrlinger KR	2007	Clin Pharmacokinet2007，46，3：	1
9	Mechanisms of disease:defensins in gastrointestinal diseases显示文摘	Wehkamp J Fellermann K Herrlinger KR	2005	Nat Clin Prac Gastroenterol Hepatol2005，2，9：	1
10	Efficacy, safety and tolerability of vidofludimus in patients with inflammatory bowel disease: The ENTRANCE study显示文摘	Herrlinger KR Diculescu M Fellermann K	2012	J Crohns Colitis2012，，：	1
11	Defensin pattern in chronic gastritis: HBD-2 is differentially expressed with respect to Helicobacter pylori status 显示文摘	Wehkamp J Schmidt K Herrlinger KR	2003	J C lin Pathol2003，56，5：	1
12	Tacrolimus:a new immunosuppressant for steroid refractory inflammatory bowel disease显示文摘	Fellermann K Herrlinger KR Witthoeft T	2001	Transplant Proc2001，33，：	1
13	Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmaeogenetieally guided dosing 显示文摘	Teml A Schaeffeler E Herrlinger KR	2007	Clin Pharmacokinet2007，46，：	1
14	Response of refractory colitis to intravenous or oral tacrolimus (FK506)显示文摘	Fellermann K Tanko Z Herrlinger KR	2002	Inflamm Bowel Dis2002，8，5：	1
15	Response of refractory colitis to intravenous or oral tacrolimus (FK506)显示文摘	Fellermann K Tanko Z Herrlinger KR	2002	Inflamm Bowel Dis2002，8，：	1
16	Short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis-experience in 130 patients显示文摘	Schmidt KJ Herrlinger KR Emmfich J	2013	Aliment Pharmacol Ther2013，37，：	1
17	Alterations in pulmonary function in inflammatory bowel disease are frequent and persist during remission显示文摘	Noftz MK Dalhoff K	2002	Am J Gastroenterol2002，97，2：	1
18	Innate immunity and colonic inflammation: enhanced expression of epithelial al- pha-defensins显示文摘	Wehkamp J Schwind B Herrlinger KR	2002	Digest Dis Scl2002，47，：	1
19	Human beta-defensin 2 but not beta-defensin 1 is expressed preferentially in colonic mucosa of inflammatory bowel disease 显示文摘	Wehkamp J Fellermann K Herrlinger KR	2002	Eur J Gastroenterol Hepatol2002，14，7：	1
20	Innate immunity and colonic inflammation: enhanced expression of epithelial alpha-defensins 显示文摘	Wehkamp J Schwind B Herrlinger KR	2002	Dig Dis Sci2002，47，6：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示